Invention Grant
US08541369B2 Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability
有权
成纤维细胞生长因子21变体具有改善的药理学效能和/或改进的药物稳定性
- Patent Title: Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability
- Patent Title (中): 成纤维细胞生长因子21变体具有改善的药理学效能和/或改进的药物稳定性
-
Application No.: US13626308Application Date: 2012-09-25
-
Publication No.: US08541369B2Publication Date: 2013-09-24
- Inventor: Craig Duane Dickinson , David Albert Driver , Ryan James Darling , Maigorzata Donata Gonciarz , Radmila Micanovic
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Robert B. Johnson; Andrea M. Castetter
- Main IPC: A61K38/18
- IPC: A61K38/18
Abstract:
This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
Public/Granted literature
- US20130085098A1 FIBROBLAST GROWTH FACTOR 21 VARIANTS Public/Granted day:2013-04-04
Information query
IPC分类:
